Welcome to our dedicated page for Sintx Technologies news (Ticker: SINT), a resource for investors and traders seeking the latest updates and insights on Sintx Technologies stock.
SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced ceramics and biomaterials company headquartered in Salt Lake City, Utah, with news flow centered on silicon nitride–based medical technologies, implant systems, and infection‑prevention platforms. This news page aggregates company press releases and third‑party coverage so readers can follow developments in its silicon nitride biomaterials, polymer composites, and antipathogenic fabric technologies.
Recent SINTX news highlights regulatory milestones and product launches, including U.S. FDA 510(k) clearance for the SINAPTIC Foot & Ankle Osteotomy Wedge System and the launch of OsseoSculpt, a biologic designed to complement the SINAPTIC wedge portfolio. Updates also cover the company’s focused commercialization plan around infection‑resistant silicon nitride devices and polymer composites, as well as early product revenue from OsseoSculpt.
Investors and industry observers will find coverage of strategic agreements, such as the supply agreement with EVONIK to manufacture SINTX’s proprietary SiN/PEEK compound for AI‑assisted, 3D‑printed, patient‑specific implants. News items also track SINTX’s intellectual‑property progress, including Notices of Allowance from the United States Patent and Trademark Office for composition and method patents covering antipathogenic fibrous materials and fabric technologies.
In addition, SINTX issues releases on capital markets activity and corporate events, including warrant exercises, at‑the‑market offering arrangements, and participation in investor conferences hosted by firms such as H.C. Wainwright and Sidoti & Company. These updates provide context on the company’s financing strategy and investor outreach.
By monitoring this page, readers can review SINTX news related to medical device clearances, biologic product introductions, infection‑prevention patents, financing transactions, and investor presentations, all in one place.
SINTX Technologies announced the acquisition of Technology Assessment and Transfer, Inc. (TA&T), enhancing its capabilities in the aerospace, defense, and biomedical markets. This strategic move is expected to generate immediate revenue for SINTX through TA&T’s existing relationships with commercial partners and the U.S. government. TA&T specializes in advanced ceramics, including 3D printing for medical devices and innovative materials for industrial applications. The acquisition aims to leverage synergies between the two companies to further their growth and success.
SINTX Technologies, Inc. (NASDAQ: SINT) announced the filing of its 2021 Annual Report on Form 10-K with the SEC. The company has made significant investments in 2021 to expand its biomedical, industrial/armor, and antipathogenic business segments, focusing on revenue-generating opportunities, including armor materials and biomedical implants. A conference call is scheduled for April 13, 2022, to update stakeholders. SINTX manufactures advanced ceramics at its facilities in Salt Lake City, Utah, and is dedicated to developing advanced material-based solutions.
SINTX Technologies announced a $300k Phase 1 grant from the National Institutes of Health to develop 3D printed silicon nitride and polyetherketoneketone implants for craniomaxillofacial surgery. This collaboration with Drexel University and others aims to enhance implant performance by reducing failure rates linked to infections and poor integration. Over 235,000 CMF surgeries occur annually in the U.S. with a 5.5% failure rate. The grant supports the commercialization of this innovative material that could significantly improve patient outcomes.
SINTX Technologies, Inc. (NASDAQ: SINT) announced advancements in manufacturing technologies for fabrics impregnated with silicon nitride, highlighting successful antipathogenic testing results. Recent tests showed that the embedded fabric effectively inactivated Staphylococcus Aureus and SARS-CoV-2, indicating enhanced antiviral properties. These developments reinforce SINTX's collaboration with a private European firm and mark significant milestones in the production of antipathogenic fabrics for various applications, including medical gowns and facemasks.
SINTX Technologies, Inc. (NASDAQ: SINT) announces the retirement of Chief Scientific Officer Dr. Bryan J. McEntire after 17 years. Dr. Ryan Bock, currently Director of R&D, will step in as Vice President of R&D, leading ongoing biomaterial development and expanding research on antipathogenic ceramics. Dr. McEntire has made significant contributions to the company, including research and product development for orthopedic implants made from silicon nitride. He will remain connected to SINTX in an advisory role.
SINTX Technologies recently provided a year-end business update, highlighting advancements in its biomedical, antipathogenic, and industrial segments. The company initiated joint research with leading universities under an NIH grant to develop 3D-printed silicon nitride PEEK composite spinal implants. New patent protections for antipathogenic applications offer potential commercial opportunities. Additionally, SINTX is constructing updates to its manufacturing facility for full production. Notably, the company received full forgiveness of a $509,148 SBA PPP loan, strengthening its financial position.
SINTX Technologies, Inc. (NASDAQ: SINT) announced the launch of its subsidiary SINTX Armor, signing a 10-year lease for a facility in Salt Lake City for development and manufacturing. The facility will house equipment moved from Dayton, OH, with construction updates underway to facilitate machine qualification starting December 2021. The new facility will produce advanced ceramic armor, including BoroShock and DuraShock, aimed at military and industrial applications. Revenue growth is anticipated in H2 2022 as production begins.
SINTX Technologies, Inc. (NASDAQ: SINT) announced the termination of its Patent License Agreement with O2TODAY due to delays in product development.
This follows SINTX's previous evaluation of joint efforts with O2TODAY, emphasizing its commitment to developing antiviral and antimicrobial fabrics using SINTX's patented FleX SN-AP silicon nitride powder. SINTX continues to pursue collaborations and product development in the antipathogenic fabric space, vital to its business strategy.
SINTX Technologies reported preliminary Q3 2021 revenue of approximately $240k, surpassing Q1 and Q2 revenues. Revenue stems from three sectors: spinal implants, antipathogenic fabrics, and armor. The company anticipates new revenue in Q4 2021 from open prototype orders for aerospace components and industrial applications. SINTX is focused on expanding its presence in advanced ceramics manufacturing at its FDA and ISO certified facility. A detailed business update will follow the upcoming Quarterly Report on Form 10-Q.
SINTX Technologies, Inc. (NASDAQ: SINT) announced the shipment of production quantities of a new porous, laser-textured monolithic silicon nitride implant for surgical spinal solutions. This shipment follows successful collaboration with CTL Amedica and supports a product launch expected in Q4 2021. The implants aim to enhance osseointegrative and antibacterial properties. SINTX has also submitted a provisional patent for improved manufacturing methods, supported by a Phase 1 grant from NIH. The company is actively investing in advanced manufacturing technologies and workforce recruitment.
FAQ
What is the current stock price of Sintx Technologies (SINT)?
What is the market cap of Sintx Technologies (SINT)?
